Ipsen Presents Preliminary Results Of Exploratory Proof-Of-Concept Study With Tasquinimod In Four Advanced Tumor Types At The ESMO 2014 Congress

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation at the ESMO 2014 Congress (26-30 September in Madrid) of the preliminary results of the phase II proof-of-concept clinical trial with tasquinimod in monotherapy, evaluating the compound in four advanced tumor types.

Help employers find you! Check out all the jobs and post your resume.